Genmab — November 2017
-
Genmab results http://ir.genmab.com/releasedetail.cfm?ReleaseID=1047814
-
-
der er en forsinkelse i ofa: "Optimize ofatumumab value Phase III refractory FL headline results."
er udsat til 2018 -
Genmab præsenterer nettotab og fastholder forventningerne
Omsætningen er endt lavere og indtjeningen falder drastisk for Genmab i tredje kvartal, hvor man kommer ud med røde tal på bundlinjen. Selskabet fastholder dog forventningerne.
(medwatch.dk)
-
Kan sagtens bruge spørgsmål vedr. regnskabet til Q&A i morgen. Den slags plejer vi ikke at mange af.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind